Trial reportDiabetes care2022
Efficacy of Combined Abelmoschus manihot and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial.
Open access · greenAbstract readMulticenter StudyRandomized Controlled TrialLetter
In one paragraph
Trial report in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
9.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- The effects of Okra supplementation on blood pressure, lipid profile, and inflammation in patients with prediabetes, type 2 diabetes, and diabetic nephropathy: a meta-analysis and systematic review.Nutrition & diabetes · 2026Pooled it
- Analysis of Clinical Trials Using Anti-Tumor Traditional Chinese Medicine Monomers.Drug design, development and therapy · 2024Pooled it
- Efficacy and safety of Abelmoschus manihot capsule combined with ACEI/ARB on diabetic kidney disease: a systematic review and meta analysis.Frontiers in pharmacology · 2023Pooled it
- Total flavonoids ofPharmaceutical biology · 2026Article
- Serum and Urine Metabolite Profiling Combined With Network Pharmacology to Predict the Renoprotective Mechanism of Huangkui Capsule Against Acute Kidney Injury.Biomedical chromatography : BMC · 2026Article
- Engineering ofACS omega · 2026Article
- ZhiXiaoSanZheng formula ameliorates podocyte injury in diabetic kidney disease by inhibiting ferroptosis: integrated network pharmacology and experimental validation.Chinese medicine · 2026Article
- Efficacy and safety of Abelmoschus manihot in the treatment of patients with type 2 diabetes and microalbuminuria: A multicenter randomized, open-label, parallel-controlled clinical trial.Chinese medical journal · 2026Article
- Integrated network pharmacology and bioinformatics analysis reveals MME as key target of Notoginsenoside R1 in diabetic nephropathy.BMC complementary medicine and therapies · 2026Article
- Gut Microbiota Modulation by Abelmoschus manihot (L.) Improves Circulating Metabolites and Alleviates Diabetic Nephropathy in db/db Mice.BioMed research international · 2026Article
- Huangkui capsule mitigates diabetic nephropathy via epigenetic therapy effects.Frontiers in pharmacology · 2026Article
- Gut microbial-derived metabolites: key players in kidney disease and renal fibrosis.International journal of biological sciences · 2026Review
- Article
- Natural Products as Potential Therapeutic Candidates for Diabetic Kidney Disease: Molecular Mechanisms, Translational Challenges, and Future Prospects.International journal of molecular sciences · 2025Review
- Abelmoschus manihot alleviates insulin resistance in diabetic kidney disease through attenuation of inflammation.BMC nephrology · 2025Article
- Identification of two new flavone 4'-Synthetic and systems biotechnology · 2025Article
- Inhibitory effects of herbal monomers on ferroptosis in renal fibrosis: a review and mechanistic study.Frontiers in pharmacology · 2025Review
- Total flavonoids fromFrontiers in medicine · 2025Article
- From bench to bedside: targeting ferroptosis and mitochondrial damage in the treatment of diabetic cardiomyopathy.Frontiers in endocrinology · 2025Review
- Integrating proteomics and network pharmacology to explore the relevant mechanism of Huangkui capsule in the treatment of chronic glomerulonephritis.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 2 countries.
Jing ZhaoDepartment of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Isabelle TostivintDepartment of Nephrology, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France.
Lingdong XuDepartment of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Jihan HuangCenter for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Laetitia GambottiDepartment of Clinical Research, National Cancer Institute, Boulogne-Billancourt, France.
Jean-Jacques BoffaCentre of Integrative Chinese Medicine, Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France.
Min YangDepartment of Nephrology, The First People's Hospital of Changzhou, Changzhou, China.
Ling WangDepartment of Nephrology, The First People's Hospital of Xuzhou, Xuzhou, China.
Zhuxing SunDepartment of Nephrology, Wuxi People's Hospital, Wuxi, China.
Xiaolan ChenDepartment of Nephrology, Affiliated Hospital of Nantong University, Nantong, China.
Amélie Liou-SchischmanoffCentre of Integrative Chinese Medicine, Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France.
Alain BaumelouDepartment of Nephrology, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France.
Teng MaDepartment of Nephrology, Taizhou Hospital of Traditional Chinese Medicine, Taizhou, China.
Guoyuan LuDepartment of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Ling LiDepartment of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, China.
Dai ChenDepartment of Nephrology, Changzhou Hospital of Traditional Chinese Medicine, Changzhou, China.
Laurence PiéroniDepartment of Biochemistry - Hormonology, Sorbonne University, Hospital Tenon, Paris, France.
Bingkai LiuCentre of Integrative Chinese Medicine, Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France.
Xiao QinDepartment of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Weiming HeDepartment of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Yuejuan WangDepartment of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Harvest F GuSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.ORCID 0000-0003-4578-5449
Wei SunDepartment of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Nanjing University of Chinese Medicine · CNSorbonne Université · FRChina Pharmaceutical University · CNHangzhou Hospital of Traditional Chinese Medicine · CNInstitut National du Cancer · FRNantong University · CNShanghai University of Traditional Chinese Medicine · CNSoochow University · CNThe First People's Hospital of Changzhou · CNWenzhou Medical University · CNWuxi People's Hospital · CNXuzhou Medical College · CNZhongda Hospital Southeast University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AbelmoschusDiabetes Mellitus, Type 2Diabetic NephropathiesAlbuminuriaBiphenyl CompoundsDouble-Blind MethodHumansIrbesartanTetrazolesTreatment OutcomeBiphenyl CompoundsIrbesartanTetrazoles
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.